Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nervous System Diseases × XENP 1595 × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Tauopathies 1 Neurodegenerative Diseases 1 Neurocognitive Disorders 1 Nervous System Diseases 1 Mental Disorders 1 Inflammation 1 Dementia 1 Central Nervous System Diseases 1 Brain Diseases 1 Alzheimer Disease 1

Interventions

XENP 1595 1 Clinical Laboratory Techniques 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡